Concerns and recommendations: antiplatelet agents and cancer prevention in non-alcoholic fatty liver disease

Concerns and recommendations: antiplatelet agents and cancer prevention in non-alcoholic fatty liver disease

Saved in:

Bibliographic Details
Main Authors:	Hong Tham Pham, Kim-Huong Truong-Nguyen, Minh-Hoang Tran
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Series:	Frontiers in Oncology
Subjects:	antiplatelet agent cancer non-alcoholic fatty liver disease confounding bias
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1607955/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Repurposing of Antiplatelet Agent: Cilostazol for the Treatment of Alcohol-Related Liver Disease
by: Jong Ryeol Eun, et al.
Published: (2025-05-01)

Possible Role of Platelets in the Development and Progression of Non-Alcoholic Fatty Liver Disease
by: Anna F. Sheptulina, et al.
Published: (2025-03-01)

PHARMACOGENETIC BASES OF INDIVIDUAL SENSITIVITY AND PERSONALIZED ADMINISTRATION OF ANTIPLATELET THERAPY IN DIFFERENT ETHNIC GROUPS
by: B. I. Kantemirova, et al.
Published: (2021-05-01)

DOCTOR’S ADHERENCE TO RECOMMENDATIONS GOVERNING THE ANTIPLATELET AGENTS USE IN THE CARDIOVASCULAR DISEASES PREVENTION AND TREATMENT
by: N. В. Perepech, et al.
Published: (2018-05-01)

UP TO DATE ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS AND REAL CLINICAL PRACTICE
by: S. Yu. Martsevich, et al.
Published: (2015-12-01)

THE PREVENTION OF CARDIOVASCULAR COMPLICATIONS AFTER CORONARY STENTING IN PATIENTS WITH UNSTABLE ANGINA AND RESISTANCE TO ANTIPLATELET AGENTS
by: E. A. Medvedeva, et al.
Published: (2017-12-01)

An Open Path to DAG: Navigating Causal Inference in Epidemiological Research
by: Navaneeth S. Krishna, et al.
Published: (2025-07-01)

Commentary: Evaluation of post-COVID mortality risk in cases classified as severe acute respiratory syndrome in Brazil: a longitudinal study for medium and long term
by: Julio Croda, et al.
Published: (2025-06-01)

Oral anticoagulants or antiplatelet drugs after heart valve reconstructive surgery: modern guidelines for the practitioners
by: V. P. Kuzmin, et al.
Published: (2024-04-01)

Primary Results of Our Protocol for Standardization of Perioperative Antiplatelet Agent Management on the Incidence of Epidural Hematoma and Thrombotic Complications in Posterior Cervical Surgery: A Prospective Cohort Study
by: Gentaro Kumagai, et al.
Published: (2024-11-01)

Utilization and Outcomes of Antiplatelet Therapy Following Transcatheter Aortic Valve Replacement (TAVR)
by: Agam Bansal, et al.
Published: (2025-05-01)

Prospects for the use of herbal medicine in the treatment of patients with non-alcoholic fatty liver disease
by: V. A. Akhmedov, et al.
Published: (2021-06-01)

A naphthalimide derivative exerts potent antiplatelet and antithrombotic activities without a bleeding tendency
by: Wan-Jung Lu, et al.
Published: (2025-06-01)

The study of price situation on the domestic antiplatelet market
by: Ye. А. Redkina, et al.
Published: (2017-08-01)

ANTIPLATELET THERAPY IN THE PREVENTION OF CEREBROVASCULAR ACCIDENTS
by: O. V. Rodionova, et al.
Published: (2017-03-01)

ALTERNATIVE APPROACHES TO THE USE OF TWO COMPONENT ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME: EVIDENCES, RECOMMENDATIONS AND REAL PRACTICE
by: S. R. Gilyarevskiy, et al.
Published: (2015-12-01)

Sex-specific effect of dietary fatty acids on non-alcoholic fatty liver disease
by: Jianhua Chen, et al.
Published: (2025-07-01)

Evaluation of comorbidity in patients with alcoholic cirrhosis of the liver associated with non-alcoholic fatty liver disease
by: N. R. Matkovska, et al.
Published: (2020-04-01)

ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS: THE PROBLEM OF EFFICIENCY, SAFETY AND COMPLIANCE
by: S. Yu. Martsevich, et al.
Published: (2014-07-01)

Curcumin and non-alcoholic fatty liver disease
by: Nasrin Sharifi, et al.
Published: (2024-06-01)

The impact of platelets and antiplatelets medications on immune mediation
by: Leela Morena, MD, et al.
Published: (2025-01-01)

Selective Synthesis of Fatty Alcohols over Mild Reaction Conditions via Non-Catalytic Liquid-Phase Fatty Acid Methyl Esters’ Reduction
by: Alejandro Vallejo Orrego, et al.
Published: (2023-11-01)

Efficacy of Platelet Rich Fibrin versus chitosan as a hemostatic agent following dental extraction in patients on antiplatelet therapy
by: Sourav Sarkar, et al.
Published: (2019-10-01)

Biodiesel production by direct esterification of fatty acids with propyl and butyl alcohols
by: Ferial A. Zaher, et al.
Published: (2015-12-01)

Antiplatelet Use Prior to Anticoagulant Initiation in Patients With Atrial Fibrillation-Related Ischemic Stroke: An ELAN Trial Analysis
by: Alexandros A. Polymeris, et al.
Published: (2025-05-01)

ANTIPLATELET THERAPY OF ATRIAL FIBRILLATION: FOCUS ON THE ELDERLY
by: E. А. Ushkalova, et al.
Published: (2017-03-01)

Research progress on the application of antiplatelet drugs in arteriovenous fistula for hemodialysis
by: Ma Shi-jie, et al.
Published: (2025-07-01)

Current approaches to the use of antiplatelet and anticoagulant drugs in pregnant women with thrombocytopenia caused by hemostasis activation
by: O. L. Mysik, et al.
Published: (2021-05-01)

Changes in indicators of fibrosis in patients with alcoholic liver cirrhosis associated with non-alcoholic fatty liver disease depending on the stage of cirrhosis
by: N. R. Matkovska, et al.
Published: (2020-06-01)

Dual Antiplatelet Therapy Regimens and Duration for Intracranial Stenting Procedures: Literature Review
by: Milda Paliulytė, et al.
Published: (2023-11-01)

Metabolic and Genetic Determinants of Lipid Metabolism Disruption in Non-Alcoholic Fatty Liver Disease
by: O. Yu. Kytikova, et al.
Published: (2020-05-01)

Antiplatelet Therapy in Acute Coronary Syndrome
by: I. M. Kuzmina, et al.
Published: (2022-01-01)

Balloon coronary angioplasty and parenteral antiplatelet therapy for intraoperative myocardial infarction during general surgery: An attempt to balance benefits and risks - a case report
by: Nešković Vojislava C., et al.
Published: (2020-01-01)

Features of the State of Internal Organs and the Structure of Comorbidity in Deceased Persons With Alcoholic Liver Cirrhosis, Non-alcoholic Fatty Liver Disease at the Cirrhosis Stage and Alcoholic Liver Cirrhosis Associated With Insulin Resistance and Obesity
by: N. Matkovska
Published: (2020-06-01)

Improvement of non-alcoholic fatty liver disease treatment
by: P. I. Seliverstov, et al.
Published: (2014-10-01)

RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE
by: D. H. Aynetdinova, et al.
Published: (2015-12-01)

Antiplatelet Resumption After Intracerebral Hemorrhage: A Systematic Review and Meta-Analysis
by: Sarah Yahya Alharthi, et al.
Published: (2025-07-01)

Reactive Oxygen Species as Key Molecules in the Pathogenesis of Alcoholic Fatty Liver Disease and Nonalcoholic Fatty Liver Disease: Future Perspectives
by: Zhiqing Zhang, et al.
Published: (2025-06-01)

Antiplatelet treatment and gastro-intestinal hemorrhage risk
by: D. V. Duplyakov
Published: (2005-08-01)

Practical Aspects of Clinical Manifestations, Pathogenesis and Therapy of Alcoholic Liver Disease and Non-alcoholic Fatty Liver Disease: Expert Opinion
by: V. V. Tsukanov, et al.
Published: (2023-11-01)